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Abstract
Purpose Systemic lupus erythematous (SLE) is a systemic
autoimmune inflammatory disease with both genetic and
epigenetic etiologies. Evidence suggests that deregulation
of specific genes through epigenetic mechanisms may be a
contributing factor to SLE pathology. There is increasing
evidence that DNA methyltransferase activity may be in-
volved. This study demonstrated modulation in expression
of DNA methyltransferases (DNMTs) according to ethnicity
in patients diagnosed with SLE. Furthermore, differential
expression in one of the DNMTs was found in a subset of
lupus patients on dehydroepiandrosterone (DHEA) therapy.
Methods Real-time PCR analyses of DNMT1, DNMT3A
and DNMT3B in peripheral blood mononuclear cells from
a cohort of African American and European American lupus
and non-lupus women were conducted. Also, global DNA
methylation was assessed using the MethylFlashTM methyl-
ated quantification colorimetric assay.
Results Significant increase in DNMT3A (p<0.001) was
shown in lupus patients when compared to age-matched
healthy controls. This increase was associated with a higher
SLEDI index. More striking was that expression levels for
African American (AA) women were higher than European
American women in the lupus populations. A subset of AA
women on DHEA therapy showed a significant decrease (p
<0.05) in DNMT3A expression in comparison to lupus
patients not on the therapy. DHEA is an androgenic steroid
found in low levels in the serum of lupus patients. Supple-
mentation of this hormone has been shown to be beneficial
to some lupus patients. DHEA was not shown to effect
DNMT1 or DNMT3B expression. Increased expression
was also noted in DNMT3B (p<0.05) in lupus patients
compared to age-matched healthy controls. However, no
significant difference was noted in DNMT1 (p00.2148)
expression between lupus patients and healthy controls.
Although increases were detected in de novo methyltrans-
ferases, a global decrease (p<0.001) in 5-methycytosine
was observed in lupus patients when compared to age-
matched healthy controls.
Conclusion These findings suggest that epigenetic changes
may play a critical role in the manifestations of the disease
observed among ethnic groups, particularly African Ameri-
can women who often have a higher incidence of lupus.
DHEA therapy effects on DNMT3A expression in AA
women warrant further investigation in a larger population.
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Introduction
Systemic Lupus Erythematosus (SLE) is an autoimmune
disease that has multifaceted effects on its sufferers. Wom-
en, in general, account for a significant majority of SLE
patients [1]. Furthermore, African-American and Hispanic
women have a significantly increased risk of developing
SLE as compared to their European American counterparts
[2, 3]. However, very few studies have been conducted in
these populations. Until the recent FDA approval of Ben-
lysta (belimumab), there had not been an FDA approved
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drug therapy for lupus since 1955 and physicians were
forced to use off-label medication to treat the symptoms of
SLE [4–8]. However, the use of these off-label drugs lead to
the development of toxic side effects that increased the
complication in treating individuals with SLE [9–11]. In
addition, Benlysta has been approved to treat only symp-
toms that are primarily involved with musculoskeletal and
mucoscutaneous complications with lupus [12]. Further-
more, limited data available indicate that Benlysta does not
provide a therapeutic benefit among African Americans, a
population with a high rate of susceptibility to SLE [12].
The difficulties in designing an effective pharmacological
therapy for SLE are due in part to the complexities of its
pathophysiology. Studies are being conducted to determine
why women are more susceptible than men to developing
SLE. There has been evidence that both estrogen and pro-
lactin can induce lupus in mice, leading researchers to
suggest that there is a link between estrogen, prolactin and
SLE [13]. Low serum levels of DHEA have also been
observed in some patients with lupus. Studies have shown
that DHEA treatment improves the patients’s overall quality
of life [14]. Recently, there has been increased evidence of
an epigenomic component in the pathology of SLE [15, 16].
For example, studies have shown that using 5-azacytidine (a
DNA methyltransferase inhibitor) on CD4+ T cells can lead
to autoreactivity [17]. Studies have also shown that DNA
demethylation can lead to increased activation of CD40LG,
which leads to increased expression and B cell activation.
Zhou et al. [18] showed that this increased expression of
CD40LG in women with SLE was due to reactivation of the
receptor’s gene on the inactive X chromosome. These stud-
ies are among those that show a link to epigenetic regula-
tion, specifically DNA methylation, and autoimmunity.
DNA methylation is important in development and main-
taining homeostasis of an organism. From cellular reprog-
ramming to the development of the immune system,
methylation of an organism’s genome is crucial for survival
[19, 20]. Methylation of DNA occurs in two forms: de novo
and maintenance methylation, and enzymes that catalyze
these reactions are DNA methyltransferases (DNMTs)
[21]. Of the six known DMNTs: DMNT1, DNMT2
(TRMDT1), DMNT3A, DMNT3B and DMNT3L, only
three are active methyltransferases. There is also evidence
of a link between DNMT3B function and disorders such as
immunological disorders, centromeric instability, and facial
abnormalities (ICF). Mainly, evidence associated with these
disorders are due to germline mutations in DNMT 3B [22].
There is data to support the fact that patients who suffer
from SLE have decreased levels of DMNT3B [15, 23]. Low
levels of DMNTs can lead to hypomethylation, which leads
to reactivation of otherwise silent genes. Global methylation
analyses have been conducted with SLE patients and have
shown that global hypomethylation occurs in patients with
SLE [19, 24]. Unfortunately, most of these studies were not
conducted in African American women. There is a lack of
data on epigenetic changes in African American women for
comparison observation seen in other populations. African
Americans women are diagnosed with SLE at a higher rate
than other populations in the United States. With a scarcity
of data regarding a population that makes up a significant
portion of patients diagnosed with SLE, and growing evi-
dence suggesting that DNA methylation is linked to the
pathogenesis of SLE, this investigation was conducted to
determine if ethnic differences exist in epigenetic changes.
This study examined the expression level of DNMTs 1, 3A
and 3B in a multi ethnic population that has been diagnosed
with SLE. The results from this study can contribute to
research assessing whether targeting specific methyltrans-




All subjects in this study gave their informed written con-
sent to be included in the study. The patients that participat-
ed in this study were part of the LUPUS study at the Brody
School of Medicine at East Carolina University. The cohort
for this study consisted of a total of 224 participants. The
participants representing this cohort were further catego-
rized in the following manner: 114 individuals diagnosed
as having SLE based on SLE disease activity index
(SLEDAI) score and by anti-dsDNA antibody analysis,
and 110 controls; all were age, sex and ethnicity matched.
This project was granted IRB approval from both The
Department of Health and Human Services Food and Drug
Administration and from East Carolina University.
Blood Collection and Isolation of PBMC
For our analysis, blood samples were collected by venipunc-
ture of the antecubital vein between 9:00AM–12:00PM. In
order to maintain a similar circadian pattern between our
participants with SLE and their matched control partici-
pants, collections were conducted at the same time of day
and the same day of the week. Peripheral blood cells were
isolated from whole blood using a PAXgene RNA Blood kit
(QIAGEN, Valencia, CA). Blood samples were immediately
placed in PAXgene kit at East Carolina University in Green-
ville, NC and shipped immediately in dry ice to the National
Center for Toxicological Research for analysis.
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RNA Isolation and Quantitative Real Time PCR
RNA was extracted from peripheral blood mononuclear
cells (PBMC) by using a PAXgene RNA kit (QIAGEN,
Valencia, CA). After extraction, all RNA samples were
tested for their integrity and concentration using a Bio-Rad
Experion Automated Electrophoresis System (BIO-RAD,
Hercules, CA). cDNA were synthesized from total RNA
extractions using a Clontech Advantage® RT-for-PCR Kit
(Clontech, Mountain View, CA). DNMT1, DNMT3A and
DNMT3B expression analysis was conducted using a Bio-
Rad IQ5 quantitative Real Time Polymerase Chain Reaction
Detection System (BIO-RAD, Hercules, CA). As a compar-
ison, GAPDH was selected as our housekeeping gene and
was used as an endogenous control. qRT-PCR conditions
were as follows: 50 °C for 2 min, 95 °C for 10 min (95 °C
for 10 s, 56 °C for 45 s, 72 °C for 30 s) for 30 cycles.
Relative quantitations of DNMT1, DNMT3A, and
DNMT3B mRNA expressions were normalized to GADPH
and fold changes were calculated using a 2−ΛΛCT method.
Primers utilized for both the methytransferases and GAPDH
are listed below:
Global DNA Methylation Quantification
Global methylation was conducted using a MethylFlash
Methylated DNA Quantification kit (Epigentek Inc.,
Farmingdale, NY). The instructions were followed as
outlined in the kit. Briefly, DNA (100 ng) was bound
to strip wells that were specifically treated to have a high
DNA affinity. The methylated fraction of DNA is
detected using capture and detection antibodies and then
quantified colorimetrically by reading the absorbance in a
microplate spectrophotometer. The amount of methylated
DNA is proportional to the OD intensity. The absolute
amount of methylated DNA was quantified from a stan-
dard curve. The slope of the standard curve using linear
regression was done followed by the calculation for the
percentage of methylated DNA (5-mC) in total DNA
using the below formula.
5 mC ngð Þ ¼ SampleODME3OD
Slope 2
5mC % ¼ 5mC Amount ngð Þ
S
 100
S is the amount of input sample DNA in ng. ME3 is the
negative control.
Statistical Analysis
For this study, a comparison analysis was conducted for each
of the aforementioned methyltransferases. The comparisons
included participants with SLE to our control population and
African Americans with SLE compared to European Ameri-
cans with SLE. A two-tailed MannWhitney t-test was used to
determine if significant differences existed. For comparison of
multiple groups anANOVA test was used. To compare values,
P-values of <0.05 were considered significant. All analyses
were performed using Prism.
Results
Figure 1a shows results from comparisons of expression of
DNMT1. The results from this study indicated that there
were no significant difference in the mRNA expression
levels of DNMT1 among patients with SLE compared to
aged-matched controls. There was evidence of inter-
individual variation but the means of the two groups were
not significantly different (P00.2148). DNMT1 is predom-
inantly, but not exclusively, involved with maintenance
methylation [25, 26]. Therefore, based on the results from
our DNMT1 expression analysis, maintenance methylation
may not play an active role in the disease progression of
SLE in these populations. However, results from analysis of
methyltransferases that are involved with de novo methyla-
tion demonstrated that their expression levels differ.
Figure 1b shows the results from comparison of expression
levels of DNMT3A. With a p-value less than 0.0001, anal-
ysis indicates that expression levels of DNMT3A was sig-
nificantly higher in SLE population compared to controls. In
addition, Fig. 1c shows that DNMT3B expression levels are
also significantly higher in our SLE population compared to
aged, sex and ethnicity matched controls (p<0.05). Based
on our initial results, we then proceeded to look at expres-
sion levels of methyltransferases according to ethnicity.
Figure 2a indicates that both African American and Europe-
an American women, who are diagnosed with SLE, have a
significantly higher expression level (p<0.05) of DNMT3A
compared to their respective control counterparts. What is
most surprising is the difference in DNMT3A expression
between ethnicity. It was found that African American women
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compared to European American women with SLE. Figure 2b
shows ethnic differences in DNMT3B. There was no differ-
ence in expression of DNMT3B in African American lupus
women when compared to controls (P00.9708); however,
there was a significant difference in European American lupus
women when compared to their controls (P<0.05). There
were no difference between African American and European
American lupus women (P00.3064). In comparing the mean
expression level of DNMT3A in patients with a higher SLE-
DAI (>4), expression was higher than those with SLEDAI
(<4) (P00.0120) (Table I). Furthermore, examining those
lupus patients on DHEA therapy, it was found that African
American women had a significant decrease in expression of
DNMT3A (Fig. 3). However, no effect was found on expres-
sion of DNMT1 and DNMT3B (Fig. 4). These results indicate
not only evidence of de novo methylation activity involve-
ment in the pathogenesis of SLE, but also that African Amer-
ican women with SLE had a higher expression of DNMT3A
compared to European women with SLE. Although DNMTs
3A and 3B expression levels were increased, this study also
confirmed other studies in showing a global decrease in 5-
methycytosine in lupus patients compared to age-matched
healthy controls (Fig. 5).
Discussion
Recently, emerging evidence is revealing the role of epige-
netic dysregulation in the pathogenesis of systemic lupus
erythematosus [27–31]. Epigenetics refers to heritable mod-
ifications that are known to modulate gene expression with-
out changes to DNA sequences. Epigenetic activation and
inactivation of genes involve several components, DNA
methyltransferases, histone deacetylases, histone acetylases,
methyl binding proteins, DNA methylases and in some
cases, microRNA [32–36]. Although most studies, includ-
ing this study, have shown overall global hypomethylation,
recent studies have indicated regional hypermethylation in a
recent case–control study using high-throughput methyla-
tion arrays. This study revealed the methylation status of
over 27,000 CpG sites in the promoter regions of about
15,000 genes of which 236 sites were hypomethylated and
105 sites were hypermethylation in female lupus patients
[37]. Epigenetic regulation by CpG methylation at specific
sites in T cells controls the differentiation of T helper cells
[38, 39]. Recently, a study showed that the Foxp3 gene,
which acts as the master regulator of the development of


























































Fig. 1 a Fold change (2−ΛΛCT) comparison of DNMT1 expression for
both African American and European American women with SLE vs.
aged, ethnicity and sex matched Controls. GAPDH was used as the
housekeeping gene for comparison. b Fold change (2−ΛΛCT) compar-
ison of DNMT3A expression for both African American and European
American women with SLE vs. aged, ethnicity and sex matched Con-
trols. GAPDH was used as the housekeeping gene for comparison. The
p<0.0001 which indicated there was a significant differences between
the two populations. c Fold change (2−ΛΛCT) comparison of DNMT3B
expression for both African American and European American women
with SLE vs. aged, ethnicity and sex matched Controls. GAPDH was
used as the housekeeping gene for comparison. The p<0.05 which
indicated there was significant difference between the two populations
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patients and further suggested promoter DNA methylation
as a possible mechanism [40].
This study investigated modulation of DNA methyltrans-
ferases in lupus and non-lupus patients. Although conflicting
results exist on the level of DNMTs expressed in lupus
patients, this may be due to variability in the disease activity
of the population studied. DNMT3a and DNMT3b produce de
novomethylation. These methyltransferases play an important
role in gene silencing by hypermethylation of promoter
regions within an organism’s genome. This study indicated
expression level differences in methyltransferases primarily
involved with de novo methylation among patients who are
diagnosed with SLE compared to the control population.
However, DNMT1, which is principally involved in mainte-
nance methylation, did not show a significant different ex-
pression level between lupus and non-lupus patients. Mixed
results have been found in other studies analyzing DNMT1
expression in SLE patients from other populations. For exam-
ple, in studies conducted among Taiwanese populations with
SLE, DNMT1 expression levels were significantly increased
compared to their controls [41]. But, in studies conducted
using a population with SLE from Shanghai, there was a
decrease in DNMT1 expression [19, 24]. In the present inves-
tigation, SLE patients have a significantly increased expres-
sion level of DNMT3A compared to the control population. In
addition, we observed that African American women with
SLE have significantly higher expression levels of DNMT
3A compared to European American women with SLE. High
levels of de novo methyltransferases correlates with hyper-
methylation or the silencing of specific genes through pro-
moter hypermethylation.
Our studies have further shown that those patients with a
SLEDAI of greater than four (4) had higher expression level
of DNMT3A. Although most animal studies and limited
human studies have shown increased expression of specific
genes in lupus patients, possibly through hypomethylation,
more studies are needed to identify those genes which may
be inactivated through promoter hypermethylation. A study
conducted with subjects in China showed no difference
between DNMT3A expression and DNMT3B expression
between patients with SLE and their control counterparts
[42]. The factors contributing to differences shown in dif-
ferent studies remain unknown. However, studies have
shown a correlation between increased methyltransferase
Ethnic Differences in DNMT3A Expression
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Fig. 2 a Ethnic Differences in Expression of DNMT3A. AA-Con
represents African American Women Controls, AA-L represents Afri-
can American Women with SLE, C-Con represents European Ameri-
can Women Controls and C-L represents European American Women
with SLE. b Ethnic Differences in Expression of DNMT3B. AA-Con
represents African American Women Controls, AA-L represents Afri-
can American Women with SLE, C-Con represents European Ameri-
can Women Controls and C-L represents European American Women
with SLE
Table I Comparison of DNMT3A expression with disease status
SLEDAI (>4) SLEDAI (<4)
DNMT3A 5.717±1.24 2.527±0.257 (P00.0120)
DNMT3a






















Fig. 3 Fold change (2−ΛΛCT) comparison of DNMT3A expression in
African American women with SLE vs. DHEA therapy. GAPDH was
used as the housekeeping gene for comparison. The p<0.05 which
indicated there was significant difference between those lupus patients
on DHEA and those patients without DHEA therapy
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expression and lupus patients in the active stage of the
disease. This study shows for the first time significant
changes in DNMT3A expression in African American
women. Although this study showed a contrast with other
studies in DNMT expression, it confirmed other data in
detecting an overall decrease in global 5-methylcytosine
activity in lupus patients, which could lead to hypomethy-
lation of methylated-sensitive genes. Global hypomethyla-
tion and increased methyltransferase expression and activity
have been shown in other diseases such as cancer [41]. A
number of reasons could be suggested for epigenetic differ-
ences seen among various populations, such as dietary,
occupational exposures, and viral infections [23, 24]. Stud-
ies have also shown that early life environmental influences,
such as exposure to infectious agents, can lead to modula-
tion of DNMTs expression and autoantibody production
later in life [42]. Also, because a number of medications
are often given to lupus patients to relieve symptoms, these
factors could also contribute to the epigenetic changes.
Although studies are underway to correlate patient medica-
tions with changes shown in DNMTs and global
methylation, previous studies have shown no correlation
[41]. However, our study found that a subset of African
American lupus patients receiving DHEA therapy showed
decreases in DNMT3A expression. Studies have shown low
levels of DHEA in the serum of lupus patient and that
supplemention of this hormone improved their overall qual-
ity of life [42]. The epigenome may be playing a more active
role than researchers have believed in the disease progres-
sion of SLE and may be a determining factor in active vs
inactive status of lupus patients. Indeed, several studies have
shown a role for DMNTs in autoimmunity. For example,
studies have shown that tranforming growth factor beta
(TGF-β) and 5-azacytidine (5AzadC) (a DNMT inhibitor)
can work to induce increased expression of Foxp3 in human
T cells [43]. This implies that DNMT plays a role in
human T cell development and function. In addition,
interleukin 4 (Il-4) expression, which plays a role in
differentiation and function of T-cells, is linked to
DNA methyltransferases [44]. There is also evidence
that shows interleukin 6 (Il-6), whose secretion can
cause SLE like symptoms by down regulating JunB,
can effect the nuclear translocation of DNMT1 [45, 46].
The fact that this study shows increased expression levels
of DNA methyltransferases related to de novo methylation
instead of those related to maintenance methylation may not
be by coincidence. However, the fact that there is a specific
form of methylation that is more active in lupus patient
above others provides more evidence that the epigenome is
more then just a simple observer in the disease progress of
SLE. Epigenetic targets are currently being explored for
drug development for SLE.
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Fig. 4 Fold change (2−ΛΛCT)
comparison of DNMT1 and
DNMT3A expression in
African American women with
SLE vs. DHEA therapy.
GAPDH was used as the
housekeeping gene for
comparison. There was no
significant difference between
those lupus patients on DHEA










Fig. 5 Global 5-methylcytosine levels in healthy controls and lupus
patients. A significant (p<0.05) decrease was noted in lupus patients
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